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 The immune system plays key roles in the defense of the organism.  
However, the effects of the immune system are not limited to the immune 
functions  and   have   impacts   beyond   the   anti-pathogenes   role.   
Indeed, neuroimmunology is a representative field of how the immune 
system affects non-immune biological and physio-pathological functions. 
Herein, we have selected a number of neurodegenerative diseases as 
illustrative examples to put a spotlight  on  this  important  field.  
Importantly, clarifying the links and interactions between the immune system 
and the nervous system represents key elements for the understanding 
neurodegenerative diseases since it will lead to new theories about the 
pathogenesis and the mechanisms underlying the related processes and thus, 
provide us with new data and novel tools to both describe the related 
pathways and develop new therapeutic approaches as well as diagnostic 
approaches and research methodologies based on such new discoveries. 
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1. INTRODUCTION 
Neuroimmunology, a field that combines both neurosciences and immunology, is a rapidly growing 
filed, and meetings are organized worldwide to discuss its latest advances, particularly those related to 
neurovascular and neurodegenerative diseases [1]-[8], showing the importance of this new area and the 
advances it will have. 
For instance, factors such as the loss of blood-brain barrier integrity influence numerous central 
nervous system (CNS) disorders [9] since it may allow more factors and molecule to go into the CNS which 
may have an impact on how the immune system influences the nervous system. In addition, blood soluble 
biomolecules such as adiponectin, an adipocytokine released by the adipose tissue, have important functions 
within the inflammatory processes which may have a pathophysiological role in neurodegenerative disorders 
[10]. Divers immunological cells and mediators [11],[12] have been shown to influence the nervous system 
and vice versa. Furthermore, the important roles of inflammation in initiating tissue damage have been 
strongly proved through clinical experiments; nevertheless, it is still difficult to explain the continuity of 
neurodegeneration after the damage has begun in spite of that magnetic resonance imaging (MRI) has shown 
no new inflammation [5]. Neuroimmunology needs more investigations and more light should be put on the 
different related aspects, especially for the neurodegenerative diseases in order to elucidate the related 
pathways and mechanisms both as patho-physiology process and as principles based on which novel 
therapies can be developed. 
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Neurodegenerative diseases constitute typical illustrations of the interactions between the nervous 
system and the immune system. Indeed, neuroimmunology gives divers example about how 
neuroimmunology could be a key for the medical future of these severe human pathologies. For each studies 
example, we can observe how the underlying mechanisms are described with a neuroimmunological context. 
Among the neurodegenerative diseases, Alzheimer's disease (AD) is a chronic disease characterized 
by the loose of cognitive functions and neuronal degeneration [13] with an increased prevalence in aging 
populations [14]. Pharmaceutical companies, government agencies, national AD organizations and scientific 
research centers are collaborating to find out the best approaches to manage and eventually treat AD [15]. 
Amyloid-β (Aβ) brain deposits constitute a major factor in AD pathogenesis [16] and both long-term 
potentiation and synaptic plasticity are affected by the oligomeric amyloid β (oAβ) [13]. It has been indicated 
that in AD oligomeric amyloid β has the ability to activate microglia and result in neuroinflammatory 
mechanism via the pro-inflammatory cytokine IL-1β in AD [13]. In addition, more results indicate that AD is 
caused by elevated Aβ42 fractions in the brain [17]. Risk factors for late onset AD include genetic  
component such as ɛ4 allele of Apolipoprotein E (ApoEɛ4) and variants of the TREM2 gene [14]. 
Importantly, TREM2 receptor, that has immune function, has been proposed as a potential pharmaceutical 
target in AD [14]. On the other hand, a set of nonsteroidal anti-inflammatory drugs (NSAIDs) have been able 
to reduce Aβ42 is divers researches [17]. These show more potential implications of the inflammatory 
processes within the AD pathogenesis. 
For AD patients with peptic ulcers, a reduction in progression of dementia was observed after the 
eradication of H. pylori [18] showing another potential link between the immune function and the neuro- 
symptoms, probably mediated by an inflammatory process. Moreover, considering the hypothesis of amyloid 
cascade for AD, a lot of researches have recently focused on vaccine therapy for this disease through 
injectable immunization, which has shown therapeutic efficiency in mice, nevertheless, it has shown severe 
adverse reactions when applied clinically, and it constitutes a challenge that many researchers are working to 
overcome [19]. 
Multiple sclerosis (MS) is another autoimmune disease mediated by T cells [20] that targets the 
CNS myelin via a chain of immune pathway reactions [21]. Yet, although the antibodies roles in MS are not 
very clarified, many findings support those antibodies have pathobiological roles within the pathogenic 
processes of MS [22]. Moreover, many immunotherapies exist for MS [21], these therapies are divided based 
on their targets and pharmacological approaches. The progress made in understanding MS disease 
mechanisms and new therapies development is highly noticeable mainly thanks to the exploitation of 
magnetic resonance imaging (MRI) technique capacities [5] as a diagnosis and evaluation tool. 
Myasthenia gravis (MG) represents also an autoimmune disease in which proteins of the 
postsynaptic membrane in the neuromuscular junction are targeted by autoantibodies that the body produces 
[23]. MG is characterized by fluctuating muscle weakness [24]. This rare disease involves T-cell (Treg) 
differentiation and NF-κB signaling pathway within the patho-processes [23]. It is also important to study the 
potential predictive factors associated with such diseases. Recently, a work has been done over a short period 
of time in Japan to investigate myasthenia gravis disease predictive factors that cause the increased incidence 
of elevation of the titer of anti-acetylcholine receptor antibodies in patients living in Kanazawa city [25]. It 
has been found that patients with late-onset myasthenia gravis had a higher incidence of anti-Acetyl choline 
receptors antibody titer elevation compared to others with early-onset MG, and that thymus removal enabled 
the prevention of the increase of the antibody titer in patients with non thymoma-related myasthenia gravis 
[25]. These and other results further highlight the immunological involvement in this neurological disease. 
Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome [26],[27] that represents 
another illustration of the neuroimmunological interactions. It is characterized by opsoclonus, myoclonus, 
and ataxia [26],[28] and it has been associated with neuroblastic tumors in children [26]. For this rare 
disorder with neurological component, it has been suggested that this syndrome could be another 
manifestation of HIV infection [29] and the implication of B cell mechanisms within the disease pathway 
[30] point the immunological aspects of this syndromes considered as a neuroinflammatory disorder [31]. 
Thus, suppose that therapies might be provided by neuroimmunology. 
 
 
3. DISCUSSION 
These examples point out the applications neuroimmunology could have in neurological diseases 
and illustrate the perspectives that the recent findings would lead to. Therefore, we expect that the data 
provided by neuroimmunology will not only allow us to map the pathway of some pathological and 
physiological process, but will also allow us to develop new treatments such as the possible implication and 
therapeutic use of cytokines, cytokine antagonists, and soluble adhesion molecules in some 
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cells by hepatocyte growth factor has been shown to limit mouse autoimmune neuroinflammation [32] which 
represent a hope for the neuroinflammatory disorders. 
Importantly, G protein coupled receptors (GPCRs) that exist and play important functions within 
both the immune system and nervous system represent an important target within the modern pharmacology 
[33]-[36] thus, further investigation on the GPCRs [37]-[39] remain important for solving future challenges 
that will face neuroimmunology especially from a pharmacological perspective [40] including drug design 
and discovery [41],[42] and drug screening [43],[44]. 
 
 
4. PERSPECTIVES 
It is important to develop new techniques and novel approaches [45],[46] with higher sensitivity 
than those existing at the moment, in order to elucidate more clearly the mechanisms of these 
neurodegenerative diseases, particularly techniques able to detect the very tiny amounts of immune factors. 
Indeed, increasing number of evidences is pointing immune factors have been shown to play roles in divers 
non-immune pathways and non-immune pathways can influence the immune functions (or be linked to) 
including obesity [47], diabetes [48], nutrition-related [49], schizophrenia [50], brain function [51] and aging-
related changes to immunity [52]. 
 
 
5. CONCLUSION 
Further investigations involving multidisciplinary approaches remain required to elucidate the key 
features of the different aspects of the neuroimmunology from divers fields. Such goal can be achieved 
especially by applying modern methods which would allow as a deeper understanding of the different 
immune functions and their implications within the neurodegenerative diseases, not only via the 
inflammatory processes but also through the different cellular and molecular pathways. Importantly, a better 
understanding of the neuroimmunological concepts within the context of neurodegenerative diseases would 
surely allow us to improve the current therapeutic approaches via controlling drugs side effects and 
developing novel treatments. 
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